Incyte Biosciences Japan

Incyte Biosciences Japan is the Japanese subsidiary of Incyte, a global biopharmaceutical company headquartered in Delaware, USA. The company specializes in the discovery, development, and commercialization of novel therapeutics, with a primary focus on oncology, hematology, and inflammation and autoimmunity. Since establishing its direct presence in Japan, the company has successfully launched key products such as Pemazyre for the treatment of FGFR2-positive biliary tract cancer and Minjuvi for diffuse large B-cell lymphoma. Incyte is a pioneer in Janus kinase (JAK) inhibition, and its Japanese operations are integral to expanding the clinical reach of its targeted therapy pipeline. The company continues to advance several late-stage programs in dermatology and solid tumors to address significant unmet medical needs in the Japanese market.